PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.
Evidence
Molecular Subtyping Improves Diagnostic Stratification of Patients with Primary Breast Cancer into Prognostically-Defined Risk Groups
PUBLICATION: Breast Cancer Res Treat (2015) 154: 81. https://doi.org/10.1007/s10549-015-3587-9. AUTHORS: Katharine Yao, Robert Goldschmidt, Mary TurkJelle Wesseling, Lisette Stork-Sloots, Femke de Snoo, Massimo Cristofanilli SUMMARY: Retrospective, observational study comparing MP+BP subtyping with long-term outcomes: MammaPrint low-risk patients had a 10-year DMFS of 96 % (95 %CI 92.8–99.4), while MammaPrint high-risk Read More
Application of a 70-Gene Expression Profile to Japanese Breast Cancer Patients
PUBLICATION: Breast Care 2015;10:118-122 https://doi.org/10.1159/000376562. AUTHORS: Shimizu H., Horimoto Y., Arakawa A., Sonoue H., Kurata M., Kosaka T., Nakai K., Himuro T., Tokuda E., Takahashi Y., Taira F., Ito M., Abe I., Senuma K., Stork-Sloots L., de Snoo F., Saito M. SUMMARY: Of 38 cases judged to be at intermediate Read More
Gene Expression Profiling to Predict the Risk of Locoregional Recurrence in Breast Cancer: A Pooled Analysis
PUBLICATION: Breast Cancer Res Treat (2014) 148: 599. https://doi.org/10.1007/s10549-014-3188-z. AUTHORS: C.A. Drukker, S.G. Elias, M.V. Nijenhuis, J. Wesseling, H. Bartelink, P. Elkhuizen, B. Fowble, P.W. Whitworth, R.R. Patel, F.A. de Snoo, L.J. van ’t Veer, P.D. Beitsch, E.J. Th. Rutgers SUMMARY: After a median follow-up of 8.96 years with 87 Read More
Genomic Profile of Breast Cancer: Cost-Effectiveness Analysis from the Spanish National Healthcare System Perspective
PUBLICATION: Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):889-99. doi: 10.1586/14737167.2014.957185. Epub 2014 Sep 12. AUTHORS: Seguí M.Á., Crespo C., Cortés J., Lluch A., Brosa M., Becerra V., Chiavenna S.M., Gracia A. SUMMARY: A 70-gene signature showed a life expectancy of 23.55 years at lifetime. Life expectancy was lower for 21-gene Read More
Molecular Subtyping Predicts Pathologic Tumor Response in Early-Stage Breast Cancer Treated with Neoadjuvant Docetaxel Plus Capecitabine with or without Trastuzumab Chemotherapy
PUBLICATION: Med Oncol. (2014) 31: 163. https://doi.org/10.1007/s12032-014-0163-9. AUTHORS: Soley Bayraktar, Melanie Royce, Lisette Stork-Sloots, Femke de Snoo, Stefan Glück SUMMARY: The overall pCR plus npCR rate was 25 % (30/122). Stratified by BluePrint/MammaPrint, patients of HER2 type had the best response (59 %), while luminal A (7 %) and B Read More
The Multigene Signature MammaPrint Impacts on Multidisciplinary Team Decisions in ER+, HER2− Early Breast Cancer
PUBLICATION: British Journal of Cancer, volume 111, pages 837–842 (26 August 2014). AUTHORS: R. Exner, Z. Bago-Horvath, R. Bartsch, M. Mittlboeck, V.P. Retèl, F. Fitzal, M. Rudas, C. Singer, G. Pfeiler, M. Gnant, R. Jakesz, P. Dubsky SUMMARY: According to MammaPrint (MP), 76% were low risk. In over a third Read More
Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
PUBLICATION: Annals of Surgical Oncology; October 2014, Volume 21, Issue 10; pp 3261–3267. AUTHORS: Pat Whitworth, MD; Lisette Stork-Sloots, MSc; Femke A. de Snoo, MD, PhD; Paul Richards, MD; Michael Rotkis, MD; Jennifer Beatty, DO; Angela Mislowsky, MD; James V. Pellicane, MD; Bichlien Nguyen, MD; Laura Lee, MD; Charles Nash, Read More
